Literature DB >> 27079672

[Omission of adjuvant radiotherapy in ductal carcinoma in situ : 12 year-results of the ECOG-ACRIN E5194-trial].

David Krug1, Rainer Souchon2.   

Abstract

Entities:  

Mesh：

Year:  2016        PMID： 27079672     DOI： 10.1007/s00066-016-0966-z

Source DB:  PubMed          Journal:  Strahlenther Onkol        ISSN： 0179-7158            Impact factor:   3.621


× No keyword cloud information.
  9 in total

1.  Addressing Overtreatment in DCIS: What Should Physicians Do Now?

Authors:  Monica Morrow; Steven J Katz
Journal:  J Natl Cancer Inst       Date:  2015-09-30       Impact factor: 13.506

2.  [Radiotherapy also for good-risk ductal carcinoma in situ? Results from a prospective randomized RTOG trial].

Authors:  Rainer Souchon
Journal:  Strahlenther Onkol       Date:  2015-06       Impact factor: 3.621

3.  [Adjuvant radiotherapy significantly also reduces local recurrence rate for prognostically favorable DCIS].

Authors:  René Pahl; Jürgen Dunst
Journal:  Strahlenther Onkol       Date:  2015-12       Impact factor: 3.621

4.  Surgical Excision Without Radiation for Ductal Carcinoma in Situ of the Breast: 12-Year Results From the ECOG-ACRIN E5194 Study.

Authors:  Lawrence J Solin; Robert Gray; Lorie L Hughes; William C Wood; Mary Ann Lowen; Sunil S Badve; Frederick L Baehner; James N Ingle; Edith A Perez; Abram Recht; Joseph A Sparano; Nancy E Davidson
Journal:  J Clin Oncol       Date:  2015-09-14       Impact factor: 44.544

5.  RTOG 9804: a prospective randomized trial for good-risk ductal carcinoma in situ comparing radiotherapy with observation.

Authors:  Beryl McCormick; Kathryn Winter; Clifford Hudis; Henry Mark Kuerer; Eileen Rakovitch; Barbara L Smith; Nour Sneige; Jennifer Moughan; Amit Shah; Isabelle Germain; Alan C Hartford; Afshin Rashtian; Eleanor M Walker; Albert Yuen; Eric A Strom; Jeannette L Wilcox; Laura A Vallow; William Small; Anthony T Pu; Kevin Kerlin; Julia White
Journal:  J Clin Oncol       Date:  2015-01-20       Impact factor: 44.544

6.  Decreasing Recurrence Rates for Ductal Carcinoma In Situ: Analysis of 2996 Women Treated with Breast-Conserving Surgery Over 30 Years.

Authors:  Preeti Subhedar; Cristina Olcese; Sujata Patil; Monica Morrow; Kimberly J Van Zee
Journal:  Ann Surg Oncol       Date:  2015-07-28       Impact factor: 5.344

Review 7.  Radiotherapy of Ductal Carcinoma In Situ.

Authors:  David Krug; Rainer Souchon
Journal:  Breast Care (Basel)       Date:  2015-08-19       Impact factor: 2.860

Review 8.  Overview of the randomized trials of radiotherapy in ductal carcinoma in situ of the breast.

Authors:  C Correa; P McGale; C Taylor; Y Wang; M Clarke; C Davies; R Peto; N Bijker; L Solin; S Darby
Journal:  J Natl Cancer Inst Monogr       Date:  2010

9.  A multigene expression assay to predict local recurrence risk for ductal carcinoma in situ of the breast.

Authors:  Lawrence J Solin; Robert Gray; Frederick L Baehner; Steven M Butler; Lorie L Hughes; Carl Yoshizawa; Diana B Cherbavaz; Steven Shak; David L Page; George W Sledge; Nancy E Davidson; James N Ingle; Edith A Perez; William C Wood; Joseph A Sparano; Sunil Badve
Journal:  J Natl Cancer Inst       Date:  2013-05-02       Impact factor: 13.506
  9 in total
  1 in total

1.  [Optimal margins for breast-conserving surgery with whole-breast irradiation in ductal carcinoma in situ : Results of the ASTRO, ASCO, and SSO consensus guideline].

Authors:  Rainer Souchon
Journal:  Strahlenther Onkol       Date:  2017-10       Impact factor: 3.621
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.